Aurigene Oncology

A high-profile biopharma panel that included Nobel Laureate Professor Jack W. Szostak recently discussed how India could invigorate its innovation ecosystem and support cutting-edge R&D. The prescript

Acrivon Therapeutics, Inc. brought its initial public offering to the US market a week later than originally planned and at different terms than it proposed a week earlier, but the cancer drug develo

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Organon Pays $73m Up Front For Ex-China

Who: Exelixis/Storm Therapeutics; Exelixis/Aurigene Discovery What: Exelixis partners with Storm on RNA-modifying enzyme therapies for cancer; the biotech also licenses a non-Hodgkin’s lymphoma can